Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10.
Influenza and other respiratory viruses（2023）
摘要
Based on the need for effective systemic, respiratory, and cellular immunity, the S1-SF-10-TA vaccine seems promising mucosal vaccine against respiratory infection of SARS-CoV-2.
更多查看译文
关键词
SARS‐CoV‐2 vaccine,mucosal adjuvant,pulmonary surfactant,respiratory mucosal immunity,trans‐airway route
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要